Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.

Diabetic cardiomyopathy is a specific disease process distinct from coronary artery disease and hypertension. The disease features cardiac remodeling stimulated by hyperglycemia of the left ventricle wall and disrupts contractile functions. Cardiac mast cells may be activated by metabolic byproducts...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhi Gang Huang, Qun Jin, Min Fan, Xiao Liang Cong, Shu Fang Han, Hai Gao, Yi Shan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7e355c25b7a94109bd911544e73f0d38
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e355c25b7a94109bd911544e73f0d38
record_format	dspace
spelling	oai:doaj.org-article:7e355c25b7a94109bd911544e73f0d382021-11-18T07:51:17ZMyocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.1932-620310.1371/journal.pone.0060827https://doaj.org/article/7e355c25b7a94109bd911544e73f0d382013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23556005/?tool=EBIhttps://doaj.org/toc/1932-6203Diabetic cardiomyopathy is a specific disease process distinct from coronary artery disease and hypertension. The disease features cardiac remodeling stimulated by hyperglycemia of the left ventricle wall and disrupts contractile functions. Cardiac mast cells may be activated by metabolic byproducts resulted from hyperglycermia and then participate in the remodeling process by releasing a multitude of cytokines and bioactive enzymes. Nedocromil, a pharmacologic stabilizer of mast cells, has been shown to normalize cytokine levels and attenuate cardiac remodeling. In this study, we describe the activation of cardiac mast cells by inducing diabetes in normal mice using streptozotocin (STZ). Next, we treated the diabetic mice with nedocromil for 12 weeks and then examined their hearts for signs of cardiac remodeling and quantified contractile function. We observed significantly impaired heart function in diabetic mice, as well as increased cardiac mast cell density and elevated mast cell secretions that correlated with gene expression and aberrant cytokine levels associated with cardiac remodeling. Nedocromil treatment halted contractile dysfunction in diabetic mice and reduced cardiac mast cell density, which correlated with reduced bioactive enzyme secretions, reduced expression of extracellular matrix remodeling factors and collagen synthesis, and normalized cytokine levels. However, the results showed nedocromil treatments did not return diabetic mice to a normal state. We concluded that manipulation of cardiac mast cell function is sufficient to attenuate cardiomyopathy stimulated by diabetes, but other cellular pathways also contribute to the disease process.Zhi Gang HuangQun JinMin FanXiao Liang CongShu Fang HanHai GaoYi ShanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e60827 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Zhi Gang Huang Qun Jin Min Fan Xiao Liang Cong Shu Fang Han Hai Gao Yi Shan Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
description	Diabetic cardiomyopathy is a specific disease process distinct from coronary artery disease and hypertension. The disease features cardiac remodeling stimulated by hyperglycemia of the left ventricle wall and disrupts contractile functions. Cardiac mast cells may be activated by metabolic byproducts resulted from hyperglycermia and then participate in the remodeling process by releasing a multitude of cytokines and bioactive enzymes. Nedocromil, a pharmacologic stabilizer of mast cells, has been shown to normalize cytokine levels and attenuate cardiac remodeling. In this study, we describe the activation of cardiac mast cells by inducing diabetes in normal mice using streptozotocin (STZ). Next, we treated the diabetic mice with nedocromil for 12 weeks and then examined their hearts for signs of cardiac remodeling and quantified contractile function. We observed significantly impaired heart function in diabetic mice, as well as increased cardiac mast cell density and elevated mast cell secretions that correlated with gene expression and aberrant cytokine levels associated with cardiac remodeling. Nedocromil treatment halted contractile dysfunction in diabetic mice and reduced cardiac mast cell density, which correlated with reduced bioactive enzyme secretions, reduced expression of extracellular matrix remodeling factors and collagen synthesis, and normalized cytokine levels. However, the results showed nedocromil treatments did not return diabetic mice to a normal state. We concluded that manipulation of cardiac mast cell function is sufficient to attenuate cardiomyopathy stimulated by diabetes, but other cellular pathways also contribute to the disease process.
format	article
author	Zhi Gang Huang Qun Jin Min Fan Xiao Liang Cong Shu Fang Han Hai Gao Yi Shan
author_facet	Zhi Gang Huang Qun Jin Min Fan Xiao Liang Cong Shu Fang Han Hai Gao Yi Shan
author_sort	Zhi Gang Huang
title	Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
title_short	Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
title_full	Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
title_fullStr	Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
title_full_unstemmed	Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
title_sort	myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/7e355c25b7a94109bd911544e73f0d38
work_keys_str_mv	AT zhiganghuang myocardialremodelingindiabeticcardiomyopathyassociatedwithcardiacmastcellactivation AT qunjin myocardialremodelingindiabeticcardiomyopathyassociatedwithcardiacmastcellactivation AT minfan myocardialremodelingindiabeticcardiomyopathyassociatedwithcardiacmastcellactivation AT xiaoliangcong myocardialremodelingindiabeticcardiomyopathyassociatedwithcardiacmastcellactivation AT shufanghan myocardialremodelingindiabeticcardiomyopathyassociatedwithcardiacmastcellactivation AT haigao myocardialremodelingindiabeticcardiomyopathyassociatedwithcardiacmastcellactivation AT yishan myocardialremodelingindiabeticcardiomyopathyassociatedwithcardiacmastcellactivation
_version_	1718422862789869568

Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.

Ejemplares similares